Introduction: The Female Sexual Function Index (FSFI) has been validated for use in many countries. It has been used for clinical and research purposes in Sweden, but the reliability and validity of the Swedish version have never been tested.
Aim: The aim of this study was to investigate the psychometric properties of the Swedish version of the FSFI.
Methods: After informed consent, 50 women with a diagnosis of hypoactive sexual desire disorder (HSDD) and 58 age-matched healthy volunteers completed the questionnaires.
Main Outcome Measures: Reliability was tested by Cronbach's alpha and test-retest by Pearson's correlation, convergent validity by correlation of the FSFI and the Sexual Function Questionnaire (SFQ), divergent validity by correlation of FSFI and the Symptoms Checklist-90-Revised (SCL-90-R), and discriminant validity by Student's t-test and chi-square test to assess differences between women with and without HSDD.
Results: Cronbach's alpha was 0.90-0.96 and test-retest reliability was good (r=0.86-0.93) for all domains in the whole sample; reliability was low for lubrication and pain in the control group. Correlations between all corresponding domains of the FSFI and the SFQ were high for the whole sample (r=0.74-0.87) and moderate to high for both the clinical and the control group. There was no correlation between most FSFI domains and the SCL-90-R. Discriminant validity was very good for each of the FSFI domains (P=0.001, t=7.05-15.58), although the controls reported relatively low scores on the desire domain. The total FSFI score was 31.37 (standard deviation [SD] 2.66) for the clinical group and 17.47 (SD 5.33) for the controls (P=0.001, t=15.99).
Conclusion: The Swedish version of the FSFI can be used as a validated and reliable instrument for assessing sexual function in women with HSDD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/jsm.12778 | DOI Listing |
EJNMMI Rep
January 2025
Department of Translational Medicine, Lund University, Lund, Sweden.
Background: Positron emission tomography/computed tomography (PET/CT) with prostate specific membrane antigen ligands (PSMA) is established for use in primary staging of prostate cancer to screen for metastases. It has also shown promise in local tumor staging, including detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI). Previous studies have shown high heterogeneity in methods and results.
View Article and Find Full Text PDFBMJ Open
December 2024
General Practice / Family Medicine, School of Public Health and Community Medicine, Sahlgrenska Academy, University of Gothenburg Institute of Medicine, Gothenburg, Sweden.
Background: Recent breakthroughs in artificial intelligence research include the development of generative pretrained transformers (GPT). ChatGPT has been shown to perform well when answering several sets of medical multiple-choice questions. However, it has not been tested for writing free-text assessments of complex cases in primary care.
View Article and Find Full Text PDFCell Death Dis
December 2024
University of Zürich, Institute of Anatomy, Winterthurerstrasse 190, 8057, Zürich, Switzerland.
The TGFβ signaling pathway is known for its pleiotropic functions in a plethora of biological processes. In melanoma, TGFβ signaling promotes invasiveness and metastasis formation. However, its involvement in the response to therapy is controversial.
View Article and Find Full Text PDFEur J Midwifery
December 2024
Department of Health Science, Mid Sweden University, Sundsvall, Sweden.
Introduction: The world needs skilled, well educated, and confident midwives, but there is a lack of instruments to measure confidence in the Swedish context. The aim was to psychometrically test and adapt the COMICE (Confidence Of Midwifery students on selected midwifery Competencies at completion of Education) questionnaire on Swedish midwifery students.
Methods: This is a national cross-sectional study of midwifery students from all 13 universities in Sweden in 2016-2017.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!